EGFR-mutated mNSCLC: Sharing Clinical Insights and Best Practices

Experts explore the current frontline treatment options for EGFR-targeted therapy, examine when combination therapy may be preferred, and discuss the importance of appropriately sequencing therapies for our patients.

EP. 1: Evaluating How the FLAURA2 OS Data Will Impact Clinical Practice

September 22nd 2025

Experts discuss emerging consensus around the value of combination therapy in EGFR-mutated metastatic NSCLC, highlighting practice-changing overall survival data from FLAURA2 and emphasizing how intensified upfront treatment may now redefine the standard of care despite added complexity and toxicity.

EP. 2: Identifying High-risk Patient Populations Benefitting From Combination Therapy in the Frontline

September 22nd 2025

Experts discuss the evolving role of combination therapy in frontline treatment for EGFR-mutated metastatic lung cancer, emphasizing that while survival data from FLAURA2 support broader use beyond traditionally defined high-risk groups, real-world factors and patient preferences continue to necessitate individualized, shared decision-making.

EP. 3: Discussing the Current NCCN Guideline Recommendations and Potential Changes Following FLAURA2 Data

September 29th 2025

Experts discuss the gap between current clinical guidelines and emerging trial data in EGFR-mutant lung cancer, highlighting calls to elevate combination therapies in treatment recommendations following robust survival benefits, while underscoring the continued importance of individualized care and patient-centered flexibility in frontline decision-making.

EP. 4: Real-World Utilization of Monotherapy and Combination Therapy in the Frontline Setting

September 29th 2025

Experts discuss the slow but growing real-world adoption of combination therapy for EGFR-mutant non–small cell lung cancer (NSCLC) despite strong FLAURA2 survival data, citing factors such as clinical inertia, comfort with monotherapy, and regional practice variations, while anticipating broader uptake as confidence, education, and infrastructure catch up with the evolving standard of care.

EP. 5: Choosing the Most Effective Frontline Treatment to Account for Patient Attrition

October 6th 2025

Experts discuss a key finding from FLAURA2 showing that many patients never reach second-line therapy, reinforcing the importance of delivering the most effective treatment—such as combination therapy—up-front, particularly when patients are fit, as real-world barriers and rapid progression may limit later opportunities for intervention.

EP. 6: The Role of the Physician in the Shared Decision-Making Process

October 6th 2025

Experts discuss the vital role of shared decision-making in lung cancer treatment, emphasizing personalized, ongoing conversations that align therapy choices with patients’ values, quality-of-life considerations, and life circumstances to support informed and compassionate care.

EP. 7: Differentiating Between the Risk-Benefit Profiles for the Combination Therapies

October 13th 2025

Experts discuss the comparative merits of FLAURA2 and MARIPOSA frontline regimens for EGFR-mutant non–small cell lung cancer, noting similar survival benefits but highlighting key differences in toxicity profiles, supportive care demands, and real-world practicality that make individualized patient counseling essential to treatment selection.

EP. 8: The Impact of SKIPirr and COCOON Protocols on Amivantamab Toxicities

October 13th 2025

Experts discuss the critical role of toxicity management in deciding whether to use amivantamab/lazertinib up-front or in later lines, highlighting the need for intensive supportive care, coordinated care teams, and structured patient education to navigate the regimen’s unique and often burdensome adverse effect profile.

EP. 9: Pemetrexed Maintenance Duration and Toxicity Management

October 20th 2025

Experts discuss the cumulative toxicities of pemetrexed in the FLAURA2 regimen, emphasizing the need for personalized, flexible approaches to maintenance therapy duration that balance ongoing efficacy with tolerability, guided by patient-specific factors and real-world clinical experience.

EP. 10: Evaluating the Impact of Subcutaneous Amivantamab Administration

October 20th 2025

Experts discuss the promise of subcutaneous (SubQ) amivantamab in improving logistical efficiency and reducing infusion-related reactions in the MARIPOSA regimen, while emphasizing that chronic toxicities persist regardless of administration route, underscoring the ongoing need for proactive monitoring, supportive care, and close clinical oversight.

EP. 11: Continuing Osimertinib in the 2L Treatment Setting: Data From COMPEL

October 27th 2025

Experts highlight evolving evidence that continuing EGFR tyrosine kinase inhibitors (TKIs) with chemotherapy after progression may improve outcomes, but emphasize that treatment sequencing decisions must be personalized based on emerging data, patient factors, and drug availability.

EP. 12: MARIPOSA-2 Toxicity Management: Amivantamab Delay vs Dose Reduction

October 27th 2025

Experts shared that while amivantamab combined with chemotherapy in MARIPOSA- 2 can cause challenging toxicities, careful dose adjustments, premedication, and vigilant monitoring help manage adverse effects and support continued treatment.

EP. 13: Resistance Patterns, the Need to Rebiopsy, and Sequencing Strategies

November 3rd 2025

Resistance management in EGFR-mutant lung cancer relies on both liquid and tissue biopsies to guide therapy, with careful interpretation of molecular findings and multidisciplinary collaboration essential to balancing precision medicine advances against patient safety and evidence-based care.

EP. 14: Can Next Generation EGFR-Targeted TKIs Improve Outcomes?

November 3rd 2025

Experts discussed how, despite several new third-generation EGFR tyrosine kinase inhibitors (TKIs) in development, the real progress in treating EGFR-mutant lung cancer is likely to come from combination therapies rather than new monotherapies, emphasizing the need for treatments that deliver meaningful improvements over current standards rather than just incremental changes.

EP. 15: The Future of Tumor Agnostic Therapies in EGFRm m NSCLC

November 10th 2025

Experts discuss the expanding treatment landscape for EGFR-mutated non–small cell lung cancer (NSCLC), highlighting emerging strategies beyond tyrosine kinase inhibitors (TKIs)—including novel immunotherapy combinations and antibody-drug conjugates (ADCs)—with particular interest in bispecific antibodies and TROP2-directed ADCs that may offer new options for patients progressing on targeted therapy, despite ongoing challenges in translating immune-based approaches into consistent survival gains.

EP. 16: Identifying the Remaining Treatment Gaps and Unanswered Questions

November 10th 2025

Experts discuss the persistent challenges in EGFR-mutated non–small cell lung cancer , including central nervous system (CNS) progression and treatment sequencing, emphasizing the urgent need for more transformative strategies beyond current combination regimens, greater inclusion of complex patient populations in trials, and the critical role of comprehensive biomarker testing and shared decision-making in delivering personalized, future-forward care.